PMID- 37745897
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230926
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Electronic)
IS  - 1178-6973 (Linking)
VI  - 16
DP  - 2023
TI  - Clinical Utility of Contezolid-Containing Regimens in 25 Cases of 
      Linezolid-Intolerable Tuberculosis Patients.
PG  - 6237-6245
LID - 10.2147/IDR.S425743 [doi]
AB  - OBJECTIVE: Linezolid is increasingly used in the treatment of multidrug-resistant 
      (MDR) M. tuberculosis (TB) with good efficacy; however, its clinical use is 
      limited by intolerable adverse events (AEs). This usually results in dose 
      adjustment or even discontinuation. Contezolid is a new oxazolidinone antibiotic 
      with in vitro antibacterial activity against MDR TB equivalent to linezolid, but 
      its safety and efficacy in MDB TB treatment has not been established. METHODS: We 
      conducted a retrospective study on 25 TB patients who received both linezolid and 
      contezolid in Beijing Chest Hospital from January 1, 2022, to January 31, 2023. 
      All patients received linezolid-containing anti-TB regimen first and then 
      switched to contezolid-containing regimens due to the intolerable 
      linezolid-related AEs. RESULTS: Most (68%, 17/25) of the patients were diagnosed 
      with RR-TB or MDR-TB. A total of 30 AEs were reported in these patients. About 
      26.7% (8/30) of the AEs were Grade 3 (severe) in severity. After switching to 
      contezolid-containing anti-TB regimens for at least 1 month, the 
      linezolid-related AEs were resolved or improved in 90% of the cases. Clinical 
      improvement was observed in all patients after treatment with 
      contezolid-containing regimen, with negative results of sputum culture and/or 
      smear for M. tuberculosis in 84% of the patients. CONCLUSION: Contezolid can be 
      the first choice instead of linezolid to combine with other anti-TB drugs if 
      necessary. Well-designed clinical trials are required to further confirm the 
      safety and efficacy of contezolid in the treatment of TB patients.
CI  - (c) 2023 Wang et al.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
FAU - Nie, Wenjuan
AU  - Nie W
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
FAU - Ma, Liping
AU  - Ma L
AUID- ORCID: 0000-0002-8460-6047
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
FAU - Geng, Ruixue
AU  - Geng R
AD  - Tuberculosis Department, The Second Hospital of Hohhot, Hohhot, People's Republic 
      of China.
FAU - Shi, Wenhui
AU  - Shi W
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
FAU - Chu, Naihui
AU  - Chu N
AD  - Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, 
      Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230919
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC10517683
OTO - NOTNLM
OT  - contezolid
OT  - linezolid
OT  - outcome
OT  - safety
OT  - tuberculosis
COIS- All authors declare that they have no conflicts of interest in this work.
EDAT- 2023/09/25 06:42
MHDA- 2023/09/25 06:43
PMCR- 2023/09/19
CRDT- 2023/09/25 05:08
PHST- 2023/07/06 00:00 [received]
PHST- 2023/09/09 00:00 [accepted]
PHST- 2023/09/25 06:43 [medline]
PHST- 2023/09/25 06:42 [pubmed]
PHST- 2023/09/25 05:08 [entrez]
PHST- 2023/09/19 00:00 [pmc-release]
AID - 425743 [pii]
AID - 10.2147/IDR.S425743 [doi]
PST - epublish
SO  - Infect Drug Resist. 2023 Sep 19;16:6237-6245. doi: 10.2147/IDR.S425743. 
      eCollection 2023.